Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced HCC patients
by Impact Journals LLCOverall survival- log rank test was used; fifteen of the 19 GH-high patients died, the median OS was 9.26 months (95% CI: 7.59, 14.59). Credit: 2022 Mohamed et al.A new research
Updated on: January 15,2024
Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced HCC patients
by Impact Journals LLCOverall survival- log rank test was used; fifteen of the 19 GH-high patients died, the median OS was 9.26 months (95% CI: 7.59, 14.59). Credit: 2022 Mohamed et al.A new research
Updated on:January 15,2024
